CHD7 and CHARGE syndrome: Heterozygous CHD7 (chromodomain helicase DNA-binding protein 7, MIM 608892) mutations have been identified in approximately 60%-70% of patients with clinically diagnosed CHARGE Syndrome and are most commonly due to de novo truncating mutations.